Divalproex, Valproate, & Developing Treatment Options for Cluster Headache Prophylaxis: Clinical Practice Considerations
Abstract Regarding the preventive treatment of CH, there are few placebo-controlled studies, meaning most treatment recommendations by physicians are limited to results from open observational studies. Additionally, existing effective therapies are believed to be underused because of our underdiagnosis of CH syndrome. Numerous treatment methods are available for different CH attack stages, making them difficult to manage. Some treatment options include inhalation of 100% oxygen or subcutaneous/intranasal administration of sumatriptan for acute cluster attacks and bridging therapy with oral prednisolone until oral prophylactic therapy is effective. Finally, drugs for the preventive treatment of CH include verapamil, lithium, divalproex sodium (Depakote), gabapentin, and topiramate. Patients suffering from CH should first be encouraged to change potentially harmful lifestyle activities, including smoking or alcohol consumption, especially during cluster periods, to minimize CH episodes as much as possible before initiating acute or prophylactic drug treatment. Cluster headaches (CH) are categorized under trigeminal autonomic headaches. CH is generally treated through acute drug therapy and preventive medicine. These excruciating, unilateral headaches are usually accompanied by conjunctival injections and lacrimation, which involve bursts of moderate to severe burning, piercing, or throbbing pain and occur acutely, episodically, or chronically. Increasing controversy continues to challenge research on CH, especially prophylactic treatment, related to the intensities of CH pain and increased ethical concerns surrounding placebo treatments, making the design of randomized controlled trials difficult. Fortunately, as new technologies and genetic studies emerge, researchers better understand the etiology of CH, allowing for more specific targeted therapies. Therefore, this review discusses divalproex, valproate, and other traditional and novel prophylactic treatment options for CH, comparing their safety profiles, pharmacodynamics, pharmacokinetics, and limitations..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:6 |
|---|---|
| Enthalten in: |
SN comprehensive clinical medicine - 6(2024), 1 vom: 29. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Orvin, Cody A. [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Cluster Headaches |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer Nature Switzerland AG 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s42399-024-01644-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR054572061 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR054572061 | ||
| 003 | DE-627 | ||
| 005 | 20240130064712.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240130s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s42399-024-01644-y |2 doi | |
| 035 | |a (DE-627)SPR054572061 | ||
| 035 | |a (SPR)s42399-024-01644-y-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Orvin, Cody A. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Divalproex, Valproate, & Developing Treatment Options for Cluster Headache Prophylaxis: Clinical Practice Considerations |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Abstract Regarding the preventive treatment of CH, there are few placebo-controlled studies, meaning most treatment recommendations by physicians are limited to results from open observational studies. Additionally, existing effective therapies are believed to be underused because of our underdiagnosis of CH syndrome. Numerous treatment methods are available for different CH attack stages, making them difficult to manage. Some treatment options include inhalation of 100% oxygen or subcutaneous/intranasal administration of sumatriptan for acute cluster attacks and bridging therapy with oral prednisolone until oral prophylactic therapy is effective. Finally, drugs for the preventive treatment of CH include verapamil, lithium, divalproex sodium (Depakote), gabapentin, and topiramate. Patients suffering from CH should first be encouraged to change potentially harmful lifestyle activities, including smoking or alcohol consumption, especially during cluster periods, to minimize CH episodes as much as possible before initiating acute or prophylactic drug treatment. Cluster headaches (CH) are categorized under trigeminal autonomic headaches. CH is generally treated through acute drug therapy and preventive medicine. These excruciating, unilateral headaches are usually accompanied by conjunctival injections and lacrimation, which involve bursts of moderate to severe burning, piercing, or throbbing pain and occur acutely, episodically, or chronically. Increasing controversy continues to challenge research on CH, especially prophylactic treatment, related to the intensities of CH pain and increased ethical concerns surrounding placebo treatments, making the design of randomized controlled trials difficult. Fortunately, as new technologies and genetic studies emerge, researchers better understand the etiology of CH, allowing for more specific targeted therapies. Therefore, this review discusses divalproex, valproate, and other traditional and novel prophylactic treatment options for CH, comparing their safety profiles, pharmacodynamics, pharmacokinetics, and limitations. | ||
| 650 | 4 | |a Cluster Headaches |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Divalproex (Depakote) |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Valproate |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Verapamil |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Prophylactic Treatment |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Lithium |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Efficacy |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Safety |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Evidence Quality |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Zaheri, Spencer C. |4 aut | |
| 700 | 1 | |a Perilloux, Dominique M. |4 aut | |
| 700 | 1 | |a Field, Elizabeth |4 aut | |
| 700 | 1 | |a Ahmadzadeh, Shahab |4 aut | |
| 700 | 1 | |a Shekoohi, Sahar |0 (orcid)0009-0007-4545-4523 |4 aut | |
| 700 | 1 | |a Kaye, Alan D. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t SN comprehensive clinical medicine |d [Cham] : Springer International Publishing, 2019 |g 6(2024), 1 vom: 29. Jan. |w (DE-627)SPR038535785 |w (DE-600)2947252-0 |x 2523-8973 |7 nnns |
| 773 | 1 | 8 | |g volume:6 |g year:2024 |g number:1 |g day:29 |g month:01 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s42399-024-01644-y |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 6 |j 2024 |e 1 |b 29 |c 01 | ||